Histogen, Inc. announced that the company's Board of Directors has appointed Richard Pascoe as Chairman of the Board of Directors and Chief Executive Officer. He will lead the Company through its next stages of clinical, corporate development and financial growth. Mr. Pascoe brings a strong track record with over 25 years of experience building and leading organizations in transition.

Most recently, he served as CEO of Apricus Biosciences, Inc. Mr. Pascoe is a member of the board of directors of two public life sciences companies; KemPharm, Inc., and Seelos Therapeutics.